{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T20:47:54Z","timestamp":1790887674116,"version":"4.1.0"},"reference-count":206,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T00:00:00Z","timestamp":1778284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T00:00:00Z","timestamp":1778284800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s00228-026-04059-x","type":"journal-article","created":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T01:58:56Z","timestamp":1778291936000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The impact of gene polymorphisms on the response of methotrexate-based treatments"],"prefix":"10.1007","volume":"82","author":[{"given":"Patricia","family":"Esper\u00f3n","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelo","family":"Vital","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Giletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,9]]},"reference":[{"issue":"2764","key":"4059_CR1","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1126\/science.106.2764.619","volume":"106","author":"S Farber","year":"1947","unstructured":"Farber S, Cutler EC, Hawkins JW, Harrison HH, Peirce EC 2nd, Lenz GG (1947) The action of pteroylglutamic conjugates on man. Science 106(2764):619\u2013621","journal-title":"Science"},{"issue":"23","key":"4059_CR2","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1056\/NEJM194806032382301","volume":"238","author":"S Farber","year":"1948","unstructured":"Farber S, Diamond LK, Mercer RD, Sylvester RF, Wolff JA (1948) Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-Aminopteroyl-Glutamic Acid (Aminopterin). N Engl J Med 238(23):787\u2013793","journal-title":"N Engl J Med"},{"key":"4059_CR3","unstructured":"Aminopterin [Internet] Bethesda (MD): National Center for Biotechnology Information (US); [cited 2025 June]. Available from: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Aminopterin#section=Information-Sources"},{"key":"4059_CR4","unstructured":"Drugs FDA [Internet]. Silver Spring (MD): U.S. Food and Drug Administration; [cited 2025 June]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2017\/208400Orig1Orig2s000MedR.pdf"},{"issue":"2","key":"4059_CR5","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1097\/00000441-195102000-00008","volume":"221","author":"R Gubner","year":"1951","unstructured":"Gubner R (1951) Therapeutic suppression of tissue reactivity. I. Comparison of the effects of cortisone and aminopterin. Am J Med Sci 221(2):169\u2013175","journal-title":"Am J Med Sci"},{"issue":"7","key":"4059_CR6","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.ad.2010.04.002","volume":"101","author":"G Carretero","year":"2010","unstructured":"Carretero G, Puig L, Dehesa L, Carrscosa JM, Ribera M, S\u00e1nches-Rega\u00f1a M et al (2010) Guidelines on the use of methotrexate in psoriasis [Metotrexato: Guia de uso en psoriasis]. Actas Dermosifiliogr 101(7):600\u2013613","journal-title":"Actas Dermosifiliogr"},{"key":"4059_CR7","unstructured":"https:\/\/www.ccjm.org\/content\/ccjom\/56\/5\/474.full.pdf"},{"issue":"3","key":"4059_CR8","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/nrrheum.2010.5","volume":"6","author":"ES Chan","year":"2010","unstructured":"Chan ES, Cronstein BN (2010) Methotrexate\u2013how does it really work? Nat Rev Rheumatol 6(3):175\u2013178. https:\/\/doi.org\/10.1038\/nrrheum.2010.5","journal-title":"Nat Rev Rheumatol"},{"key":"4059_CR9","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/980301","volume":"2014","author":"A Nassar","year":"2014","unstructured":"Nassar A, Elgohary G, Elhassan T, Nurgat Z, Mohamed SY, Aljurf M (2014) Methotrexate for the treatment of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. J Transplant 2014:980301. https:\/\/doi.org\/10.1155\/2014\/980301","journal-title":"J Transplant"},{"issue":"3","key":"4059_CR10","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1056\/NEJM199507203330301","volume":"333","author":"P Tugwell","year":"1995","unstructured":"Tugwell P, Pincus T, Yocum D, Stein M, Gluck O, Kraag G, McKendry R, Tesser J, Baker P, Wells G (1995) Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. N Engl J Med 333(3):137\u2013141","journal-title":"N Engl J Med"},{"issue":"20","key":"4059_CR11","first-page":"20","volume":"5","author":"EJ Freireich","year":"1964","unstructured":"Freireich EJ, Karon M, Frei E III (1964) Quadruple combination therapy (VAMP) for acute lymphocytic leukemia of childhood. Proc Am Assoc Cancer Res 5(20):20","journal-title":"Proc Am Assoc Cancer Res"},{"issue":"21","key":"4059_CR12","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1056\/NEJM199211193272102","volume":"327","author":"GP Canellos","year":"1992","unstructured":"Canellos GP, Anderson JR, Propert KJ, Nissen N, Cooper MR, Henderson ES, Green MR, Gottlieb A, Peterson BA (1992) Chemotherapy of advanced Hodgkin\u2019s disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 327(21):1478\u20131484","journal-title":"N Engl J Med"},{"issue":"1","key":"4059_CR13","doi-asserted-by":"publisher","first-page":"e002899","DOI":"10.1136\/rmdopen-2022-002899","volume":"9","author":"C Weber-Schoendorfer","year":"2023","unstructured":"Weber-Schoendorfer C, Diav-Citrin O (2023) Methotrexate in pregnancy: still many unanswered questions. RMD Open 9(1):e002899. https:\/\/doi.org\/10.1136\/rmdopen-2022-002899","journal-title":"RMD Open"},{"issue":"8","key":"4059_CR14","doi-asserted-by":"publisher","first-page":"505","DOI":"10.2217\/pgs-2019-0188","volume":"21","author":"P Esperon","year":"2020","unstructured":"Esperon P, Giletti A (2020) Genetic markers that could influence clinical decision making during treatment with methotrexate. Pharmacogenomics 21(8):505\u2013507","journal-title":"Pharmacogenomics"},{"key":"4059_CR15","unstructured":"Label \u2014 Jylamvo [Internet] U.S. Food and Drug Administration; [cited 2025 June]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/212479s000lbl.pdf"},{"key":"4059_CR16","unstructured":"Label \u2014 Methotrexate Tablets [Internet] U.S. Food and Drug Administration; [cited 2025 June]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/040054s015,s016,s017.pdf"},{"key":"4059_CR17","unstructured":"Label \u2014 Methotrexate Injection [Internet] U.S. Food and Drug Administration; [cited 2025 June]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/011719Orig1s136lbl.pdf"},{"key":"4059_CR18","unstructured":"Trexall O (methotrexate) [Internet]. Medscape; [cited 2025 June]. Available from: https:\/\/reference.medscape.com\/drug\/trexall-otrexup-methotrexate-343201"},{"key":"4059_CR19","unstructured":"Methotrexate [Internet] In: StatPearls. Treasure Island (FL): StatPearls Publishing; [cited 2025 June]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK556114\/"},{"key":"4059_CR20","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1200\/JCO.2006.09.9861","volume":"25","author":"LL Muldoon","year":"2007","unstructured":"Muldoon LL, Soussain C, Jahnke K et al (2007) Chemotherapy delivery issues in central nervous system malignancy: A reality check. J Clin Oncol 25:2295\u20132305","journal-title":"J Clin Oncol"},{"key":"4059_CR21","first-page":"1733","volume":"66","author":"H Breithaupt","year":"1982","unstructured":"Breithaupt H, Kuenzlen.E (1982) Pharmacokinetics of methotrexate and 7-hydroxymethotrexate following infusions of high-dose methotrexate. Cancer Treat Rep 66:1733\u20131741","journal-title":"Cancer Treat Rep"},{"key":"4059_CR22","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.2217\/pgs.14.116","volume":"15","author":"A Lima","year":"2014","unstructured":"Lima A, Sousa H, Monteiro J, Azevedo R, Medeiros R, Seabra V (2014) Genetic polymorphisms in low-dose methotrexate transporters: current relevance as methotrexate therapeutic outcome biomarkers. Pharmacogenomics 15:1611\u20131635","journal-title":"Pharmacogenomics"},{"key":"4059_CR23","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1124\/jpet.106.104364","volume":"318","author":"I Badagnani","year":"2006","unstructured":"Badagnani I, Castro RA, Taylor TR, Brett CM, Huang CC, Stryke D et al (2006) Interaction of methotrexate with organic-anion transporting polypeptide 1A2 and its genetic variants. J Pharmacol Exp Ther 318:521\u2013529","journal-title":"J Pharmacol Exp Ther"},{"key":"4059_CR24","unstructured":"Methotrexate Pathway (Cancer Cell), Pharmacodynamics and Pharmacokinetics [Internet]. PharmGKB. [cited 2025 June]. Available from: https:\/\/www.pharmgkb.org\/pathway\/PA2039"},{"issue":"8","key":"4059_CR25","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1038\/nrc3557","volume":"13","author":"JW Locasale","year":"2013","unstructured":"Locasale JW (2013) Serine, glycine and one-carbon units: cancer metabolism in full circle. Nat Rev Cancer 13(8):572\u2013583","journal-title":"Nat Rev Cancer"},{"key":"4059_CR26","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/0006-291X(73)90949-2","volume":"52","author":"CM Baugh","year":"1973","unstructured":"Baugh CM, Krumdieck CL, Nair MG (1973) Polygammaglutamyl metabolites of methotrexate. Biochem Biophys Res Commun 52:27\u201334","journal-title":"Biochem Biophys Res Commun"},{"key":"4059_CR27","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1042\/bj2360193","volume":"236","author":"JE Baggott","year":"1986","unstructured":"Baggott JE, Vaughn WH, Hudson BB (1986) Inhibition of 5-aminoimidazole4-carboxamide ribotide transformylase, adenosine deaminase and 5\u2019-adenylate deaminase by polyglutamates of methotrexate and oxidized folates and by 5-aminoimidazole-4-carboxamide riboside and ribotide. Biochem J 236:193\u2013200","journal-title":"Biochem J"},{"key":"4059_CR28","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/j.ctrv.2008.02.001","volume":"34","author":"RJ Gibson","year":"2008","unstructured":"Gibson RJ, Bowen JM, Keefe DMK (2008) Technological advances in mucositis research: new insights and new issues. Cancer Treat Rev 34:476\u2013482","journal-title":"Cancer Treat Rev"},{"key":"4059_CR29","first-page":"134","volume":"18","author":"CJD Ross","year":"2011","unstructured":"Ross CJD, Visscher H, Rassekh SR, Castro-Pastrana LI, Shereck E, Carleton B, Hayden MR (2011) Pharmacogenomics of serious adverse drug reactions in pediatric oncology. J Popul Ther Clin Pharmacol 18:134\u2013151","journal-title":"J Popul Ther Clin Pharmacol"},{"key":"4059_CR30","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.ejps.2017.09.006","volume":"109","author":"A Giletti","year":"2017","unstructured":"Giletti A, Vital M, Lorenzo M, Cardozo P, Borelli G, Gabus R et al (2017) Methotrexate pharmacogenetics in Uruguayan adults with hematological malignant diseases. Eur J Pharm Sci 109:480\u2013485. https:\/\/doi.org\/10.1016\/j.ejps.2017.09.006","journal-title":"Eur J Pharm Sci"},{"issue":"12","key":"4059_CR31","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1634\/theoncologist.2015-0164","volume":"21","author":"SC Howard","year":"2016","unstructured":"Howard SC, McCormick J, Pui CH, Buddington RK, Harvey RD (2016) Preventing and managing toxicities of high-dose methotrexate. Oncologist 21(12):1471\u20131482","journal-title":"Oncologist"},{"issue":"1","key":"4059_CR32","first-page":"27","volume":"14","author":"K Jones","year":"2024","unstructured":"Jones K, Mohassel L, Cuevo R (2024) Evaluation of a pharmacist-driven high-dose MTX monitoring protocol. J Hematol Oncol Pharm 14(1):27\u201333","journal-title":"J Hematol Oncol Pharm"},{"issue":"6","key":"4059_CR33","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/s41397-018-0047-z","volume":"18","author":"A Giletti","year":"2018","unstructured":"Giletti A, Esperon P (2018) Genetic markers in methotrexate treatments. Pharmacogenomics J 18(6):689\u2013703","journal-title":"Pharmacogenomics J"},{"key":"4059_CR34","doi-asserted-by":"crossref","unstructured":"Giletti A, Lorenzelli F, Menafra MP, Rivero F, Lorenzo M, Esper\u00f3n P (2025) Influence of FPGS rs1544105 and GGH rs3758149 Gene Polymorphisms on Methotrexate Pharmacogenetics. Biochem Genet 1\u201313","DOI":"10.1007\/s10528-025-11058-7"},{"key":"4059_CR35","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s12863-015-0191-2","volume":"16","author":"ZN Sohani","year":"2015","unstructured":"Sohani ZN, Meyre D, de Souza RJ, Joseph PG, Gandhi M, Dennis BB et al (2015) Assessing the quality of published genetic association studies in meta-analyses: the quality of genetic studies (Q-Genie) tool. BMC Genet 16:50. https:\/\/doi.org\/10.1186\/s12863-015-0191-2","journal-title":"BMC Genet"},{"key":"4059_CR36","doi-asserted-by":"publisher","first-page":"152","DOI":"10.20452\/pamw.2707","volume":"125","author":"J \u015awierkot","year":"2015","unstructured":"\u015awierkot J, \u015al\u0119zak R, Karpi\u0144ski P, Paw\u0142owska J, Noga L, Szechi\u0144ski J et al (2015) Associations between single-nucleotide polymorphisms of RFC-1, GGH, MTHFR, TYMS, and TCII genes and the efficacy and toxicity of methotrexate treatment in patients with rheumatoid arthritis. Pol Arch Intern Med 125:152\u2013161","journal-title":"Pol Arch Intern Med"},{"key":"4059_CR37","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1038\/sj.jid.5700808","volume":"127","author":"E Campalani","year":"2007","unstructured":"Campalani E, Arenas M, Marinaki AM, Lewis CM, Barker JN, Smith CH (2007) Polymorphisms in folate, pyrimidine, and purine metabolism are associated with efficacy and toxicity of methotrexate in psoriasis. J Invest Dermatol 127:1860\u20131867","journal-title":"J Invest Dermatol"},{"issue":"5","key":"4059_CR38","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1111\/bcp.16017","volume":"90","author":"J Salazar","year":"2024","unstructured":"Salazar J, Garcia-Planella E, Fern\u00e1ndez\u2010Clotet A, Esteve M, Gisbert JP, Busquets D et al (2024) Genetic biomarkers of methotrexate response and safety in Crohn\u2019s disease: data from the Spanish ENEIDA registry. Br J Clin Pharmacol 90(5):1301\u20131311","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"4059_CR39","doi-asserted-by":"publisher","DOI":"10.3892\/br.2020.1341","volume":"13","author":"J Londono","year":"2020","unstructured":"Londono J, Saldarriaga EL, Rueda JC, Giraldo-Bustos R, Angarita JI, Restrepo L (2020) Pharmacogenetic aspects of methotrexate in a cohort of Colombian patients with rheumatoid arthritis. Biomed Rep 13(4):34","journal-title":"Biomed Rep"},{"issue":"12","key":"4059_CR40","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics16121585","volume":"16","author":"J Salazar","year":"2024","unstructured":"Salazar J, Arranz MJ, Martin-Broto J, Bautista F, Mart\u00ednez-Garc\u00eda J, Mart\u00ednez-Trufero J et al (2024) Pharmacogenetics of neoadjuvant MAP chemotherapy in localized osteosarcoma: a study based on data from the GEIS-33 protocol. Pharmaceutics 16(12):1585","journal-title":"Pharmaceutics"},{"key":"4059_CR41","doi-asserted-by":"publisher","first-page":"757464","DOI":"10.3389\/fphar.2021.757464","volume":"12","author":"Z Song","year":"2021","unstructured":"Song Z, Hu Y, Liu S, Jiang D, Yi Z, Benjamin MM, Zhao R (2021) The role of genetic polymorphisms in high-dose methotrexate toxicity and response in hematological malignancies: a systematic review and meta-analysis. Front pharmacol 12:757464","journal-title":"Front pharmacol"},{"issue":"11","key":"4059_CR42","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1002\/jcph.1446","volume":"59","author":"S Lv","year":"2019","unstructured":"Lv S, Fan H, Yang H, Huang J, Li J, Shu X et al (2019) Membrane-spanning protein genetic polymorphisms related to methotrexate therapeutic outcomes in a Chinese rheumatoid arthritis population. J Clin Pharmacol 59(11):1471\u20131476","journal-title":"J Clin Pharmacol"},{"issue":"9","key":"4059_CR43","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1111\/jdv.16440","volume":"34","author":"M Chen","year":"2020","unstructured":"Chen M, Chen W, Liu P, Yan K, Lv C, Zhang M et al (2020) The impacts of gene polymorphisms on methotrexate in Chinese psoriatic patients. J Eur Acad Dermatol Venereol 34(9):2059\u20132065","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"4059_CR44","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.intimp.2016.05.012","volume":"38","author":"X Li","year":"2016","unstructured":"Li X, Hu M, Li W, Gu L, Chen M, Ding H et al (2016) The association between reduced folate carrier-1 gene 80G\/A polymorphism and methotrexate efficacy or methotrexate related-toxicity in rheumatoid arthritis: a meta-analysis. Int Immunopharmacol 38:8\u201315","journal-title":"Int Immunopharmacol"},{"key":"4059_CR45","first-page":"385","volume":"15","author":"S Jabeen","year":"2015","unstructured":"Jabeen S, Holmboe L, Aln\u00e6s GIG, Andersen AM, Hall KS, Kristensen VN (2015) Impact of genetic variants of RFC1, DHFR and MTHFR in osteosarcoma patients treated with high-dose methotrexate. Pharm J 15:385\u2013390","journal-title":"Pharm J"},{"key":"4059_CR46","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1002\/art.38331","volume":"66","author":"TN Kung","year":"2014","unstructured":"Kung TN, Dennis J, Ma Y, Xie G, Bykerk V, Pope J et al (2014) RFC1 80G\u2009>\u2009A is a genetic determinant of methotrexate efficacy in rheumatoid arthritis: a human genome epidemiologic review and meta-analysis of observational studies. Arthritis Rheumatol 66:1111\u20131120","journal-title":"Arthritis Rheumatol"},{"key":"4059_CR47","first-page":"404","volume":"7","author":"M Drozdzik","year":"2007","unstructured":"Drozdzik M, Rudas T, Pawlik A, Gornik W, Kurzawski M, Herczynska M (2007) Reduced folate carrier-1 80G\u2009>\u2009A polymorphism affects methotrexate treatment outcome in rheumatoid arthritis. Pharm J 7:404\u2013407","journal-title":"Pharm J"},{"issue":"12","key":"4059_CR48","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1002\/jcph.1252","volume":"58","author":"G Lui","year":"2018","unstructured":"Lui G, Treluyer JM, Fresneau B, Piperno-Neumann S, Gaspar N, Corradini N (2018) A pharmacokinetic and pharmacogenetic analysis of osteosarcoma patients treated with high\u2010dose methotrexate: data from the OS2006\/Sarcoma\u201009 trial. J Clin Pharmaco 58(12):1541\u20131549","journal-title":"J Clin Pharmaco"},{"issue":"3","key":"4059_CR49","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1007\/s10067-024-06892-w","volume":"43","author":"AM Nomair","year":"2024","unstructured":"Nomair AM, Abdelati A, Dwedar FI, Elnemr R, Kamel YN, Nomeir HM (2024) The impact of folate pathway variants on the outcome of methotrexate therapy in rheumatoid arthritis patients. Clin Rheumatol 43(3):971\u2013983","journal-title":"Clin Rheumatol"},{"issue":"2","key":"4059_CR50","doi-asserted-by":"publisher","DOI":"10.1177\/0300060519879588","volume":"48","author":"S Wang","year":"2019","unstructured":"Wang S, Zuo S, Liu Z, Ji X, Yao Z, Wang X (2019) Association of MTHFR and RFC1 gene polymorphisms with methotrexate efficacy and toxicity in Chinese Han patients with rheumatoid arthritis. J Int Med Res 48(2):0300060519879588","journal-title":"J Int Med Res"},{"issue":"18","key":"4059_CR51","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.2217\/pgs.15.145","volume":"16","author":"Y Ghodke-Puranik","year":"2015","unstructured":"Ghodke-Puranik Y, Puranik AS, Shintre P, Joshi K, Patwardhan B, Lamba J et al (2015) Folate metabolic pathway single nucleotide polymorphisms: A predictive pharmacogenetic marker of methotrexate response in Indian (Asian) patients with rheumatoid arthritis. Pharmacogenomics 16(18):2019\u20132034","journal-title":"Pharmacogenomics"},{"key":"4059_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2021.103312","volume":"161","author":"H Maagdenberg","year":"2021","unstructured":"Maagdenberg H, Oosterom N, Zanen J, Gemmati D, Windsor RE, Heil SG et al (2021) Genetic variants associated with methotrexate-induced mucositis in cancer treatment: a systematic review and meta-analysis. Crit Rev Oncol Hematol 161:103312","journal-title":"Crit Rev Oncol Hematol"},{"key":"4059_CR53","doi-asserted-by":"publisher","first-page":"50","DOI":"10.5045\/br.2016.51.1.50","volume":"51","author":"JA Park","year":"2016","unstructured":"Park JA, Shin HY (2016) Influence of genetic polymorphisms in the folate pathway on toxicity after high-dose methotrexate treatment in pediatric osteosarcoma. Blood Res 51:50\u201357","journal-title":"Blood Res"},{"key":"4059_CR54","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1007\/s00228-011-1046-z","volume":"67","author":"B Faganel Kotnik","year":"2011","unstructured":"Faganel Kotnik B, Grabnar I, Bohanec Grabar P, Dol\u017ean V, Jazbec J (2011) Association of genetic polymorphism in the folate metabolic pathway with methotrexate pharmacokinetics and toxicity in childhood acute lymphoblastic leukaemia and malignant lymphoma. Eur J Clin Pharmacol 67:993\u20131006","journal-title":"Eur J Clin Pharmacol"},{"key":"4059_CR55","doi-asserted-by":"publisher","first-page":"4671","DOI":"10.1182\/blood-2010-01-256958","volume":"115","author":"J Gregers","year":"2010","unstructured":"Gregers J, Christensen IJ, Dalhoff K, Lausen B, Schroeder H, Rosthoej S et al (2010) The association of reduced folate carrier 80G\u2009>\u2009A polymorphism to outcome in childhood acute lymphoblastic leukemia interacts with chromosome 21 copy number. Blood 115:4671\u20134677","journal-title":"Blood"},{"key":"4059_CR56","doi-asserted-by":"publisher","first-page":"4151","DOI":"10.1182\/blood-2006-10-054528","volume":"109","author":"S Kishi","year":"2007","unstructured":"Kishi S, Cheng C, French D, Pei D, Das S, Cook EH et al (2007) Ancestry and pharmacogenetics of antileukemic drug toxicity. Blood 109:4151\u20134157","journal-title":"Blood"},{"issue":"4","key":"4059_CR57","doi-asserted-by":"publisher","first-page":"468","DOI":"10.3390\/genes11040468","volume":"11","author":"N Kotur","year":"2020","unstructured":"Kotur N, Lazic J, Ristivojevic B, Stankovic B, Gasic V, Dokmanovic L et al (2020) Pharmacogenomic markers of methotrexate response in the consolidation phase of pediatric acute lymphoblastic leukemia treatment. Genes 11(4):468","journal-title":"Genes"},{"issue":"6","key":"4059_CR58","first-page":"800","volume":"23","author":"MA Esmaili","year":"2020","unstructured":"Esmaili MA, Kazemi A, Faranoush M, Mellstedt H, Zaker F, Safa M et al (2020) Polymorphisms within methotrexate pathway genes: relationship between plasma methotrexate levels, toxicity experienced and outcome in pediatric acute lymphoblastic leukemia. Iran J Basic Med Sci 23(6):800\u2013809","journal-title":"Iran J Basic Med Sci"},{"issue":"7","key":"4059_CR59","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics12071560","volume":"12","author":"HY Abdallah","year":"2022","unstructured":"Abdallah HY, Ibrahim ME, Abd El-Fadeal NM, Ali DA, Elsehrawy GG, Badr RE, Hassoba HM (2022) Pharmacogenomics of methotrexate pathway in rheumatoid arthritis patients: approach toward personalized medicine. Diagnostics 12(7):1560. https:\/\/doi.org\/10.3390\/diagnostics12071560","journal-title":"Diagnostics"},{"issue":"3","key":"4059_CR60","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1002\/phar.2779","volume":"43","author":"M Zobeck","year":"2023","unstructured":"Zobeck M, Bernhardt MB, Kamdar KY, Rabin KR, Lupo PJ, Scheurer ME (2023) Novel and replicated clinical and genetic risk factors for toxicity from high-dose methotrexate in pediatric acute lymphoblastic leukemia. Pharmacotherapy 43(3):205\u2013214","journal-title":"Pharmacotherapy"},{"key":"4059_CR61","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2023.106669","volume":"193","author":"O Campagne","year":"2024","unstructured":"Campagne O, Huang J, Lin T, Reddick WE, Selvo NS, Onar-Thomas A et al (2024) Population pharmacokinetics of methotrexate and 7-hydroxymethotrexate and delayed excretion in infants and young children with brain tumors. Eur J Pharm Sci 193:106669","journal-title":"Eur J Pharm Sci"},{"issue":"10","key":"4059_CR62","doi-asserted-by":"publisher","first-page":"11537","DOI":"10.3390\/cimb46100685","volume":"46","author":"V Karpa","year":"2024","unstructured":"Karpa V, Kalinderi K, Gavriilaki E, Antari V, Hatzipantelis E, Katopodi T et al (2024) Association of SLC19A1 gene polymorphisms and its regulatory miRNAs with methotrexate toxicity in children with acute lymphoblastic leukemia. Curr Issues Mol Biol 46(10):11537\u201311547","journal-title":"Curr Issues Mol Biol"},{"issue":"5","key":"4059_CR63","doi-asserted-by":"publisher","first-page":"e28858","DOI":"10.1002\/pbc.28858","volume":"68","author":"Y Cheng","year":"2021","unstructured":"Cheng Y, Chen MH, Zhuang Q, Lin BJ, Chen YY, Yang L et al (2021) Genetic factors involved in delayed methotrexate elimination in children with acute lymphoblastic leukemia. Pediatr Blood Cancer 68(5):e28858","journal-title":"Pediatr Blood Cancer"},{"key":"4059_CR64","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.leukres.2018.09.003","volume":"74","author":"DC de Carvalho","year":"2018","unstructured":"de Carvalho DC, Wanderley AV, Dos Santos AMR, Fernandes MR, Cohen Lima de Castro AN, Leit\u00e3o LPC et al (2018) Pharmacogenomics and variations in the risk of toxicity during the consolidation\/maintenance phases of the treatment of pediatric B-cell leukemia patients from an admixed population in the Brazilian Amazon. Leuk Res 74:10\u201313","journal-title":"Leuk Res"},{"issue":"4","key":"4059_CR65","first-page":"6109","volume":"8","author":"J Li","year":"2015","unstructured":"Li J, Wang XR, Zhai XW, Wang HS, Qian XW, Miao H et al (2015) Association of SLCO1B1 gene polymorphisms with toxicity response of high dose methotrexate chemotherapy in childhood acute lymphoblastic leukemia. Int J Clin Exp Med 8(4):6109","journal-title":"Int J Clin Exp Med"},{"issue":"2","key":"4059_CR66","first-page":"2","volume":"6","author":"XM Pay\u00e1","year":"2015","unstructured":"Pay\u00e1 XM, Garc\u00eda JS, Cid AR, Catal\u00e1 JC, Cervellera MIGC, Fern\u00e1ndez CC (2015) Marcadores gen\u00e9ticos de eficacia y toxicidad a metotrexato en una poblaci\u00f3n espa\u00f1ola con artritis reumatoide. Rev Soc Val Reumatol 6(2):2\u201313","journal-title":"Rev Soc Val Reumatol"},{"key":"4059_CR67","doi-asserted-by":"publisher","first-page":"204062232091602","DOI":"10.1177\/2040622320916026","volume":"11","author":"J Huang","year":"2020","unstructured":"Huang J, Fan H, Qiu Q, Liu K, Lv S, Li J et al (2020) Are gene polymorphisms related to adverse events of methotrexate in patients with rheumatoid arthritis? A retrospective cohort study based on an updated meta-analysis. Ther Adv Chronic Dis 11:2040622320916026","journal-title":"Ther Adv Chronic Dis"},{"issue":"4","key":"4059_CR68","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1080\/17512433.2023.2194630","volume":"16","author":"Z Wu","year":"2023","unstructured":"Wu Z, Li Z, Qiu X, Zhong M, Ding T (2023) Germline genetic variations in methotrexate pathway are associated with pharmacokinetics, outcome, and toxicity in patients with primary central nervous system lymphoma. Expert Rev Clin Pharmacol 16(4):371\u2013381. https:\/\/doi.org\/10.1080\/17512433.2023.2194630","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"1","key":"4059_CR69","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-60334-w","volume":"14","author":"P Pitakkitnukun","year":"2024","unstructured":"Pitakkitnukun P, Pongpitakmetha T, Suttichet TB, Sukkummee W, Chariyavilaskul P, Polprasert C (2024) Genetic polymorphisms and clinical parameters associated with renal toxicity in Thai hematologic malignancy patients receiving high dose methotrexate. Sci Rep 14(1):9695. https:\/\/doi.org\/10.1038\/s41598-024-60334-w","journal-title":"Sci Rep"},{"issue":"2","key":"4059_CR70","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1111\/j.1365-2133.2008.08898.x","volume":"160","author":"RB Warren","year":"2009","unstructured":"Warren RB, Smith RL, Campalani E, Eyre S, Smith CH, Barker JNWN et al (2009) Outcomes of methotrexate therapy for psoriasis and relationship to genetic polymorphisms. Br J Dermatol 160(2):438\u2013441","journal-title":"Br J Dermatol"},{"issue":"1","key":"4059_CR71","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s10067-019-04770-4","volume":"39","author":"A Sandhu","year":"2020","unstructured":"Sandhu A, Dhir V, Ahmad S, Dhawan V, Kaur J, Bhatnagar A et al (2020) Clinico-genetic model to predict methotrexate intolerance in rheumatoid arthritis. Clin Rheumatol 39(1):201\u2013206","journal-title":"Clin Rheumatol"},{"issue":"12","key":"4059_CR72","doi-asserted-by":"publisher","first-page":"3221","DOI":"10.1007\/s10067-018-4206-z","volume":"37","author":"A Sandhu","year":"2018","unstructured":"Sandhu A, Ahmad S, Kaur J, Bhatnagar A, Dhawan V, Dhir V (2018) Do SNPs in folate pharmacokinetic pathway alter levels of intracellular methotrexate polyglutamates and affect response? A prospective study in Indian patients. Clin Rheumatol 37(12):3221\u20133228","journal-title":"Clin Rheumatol"},{"key":"4059_CR73","doi-asserted-by":"publisher","first-page":"e2200580","DOI":"10.1200\/PO.22.00580","volume":"7","author":"T Larkin","year":"2023","unstructured":"Larkin T, Kashif R, Elsayed AH, Greer B, Mangrola K, Rafiee R et al (2023) Polygenic pharmacogenomic markers as predictors of toxicity phenotypes in the treatment of acute lymphoblastic leukemia: a single-center study. JCO Precis Oncol 7:e2200580. https:\/\/doi.org\/10.1200\/PO.22.00580","journal-title":"JCO Precis Oncol"},{"key":"4059_CR74","first-page":"478","volume":"28","author":"Z Huang","year":"2017","unstructured":"Huang Z, Tong HF, Qian JC, Wang JX, Li Y, Chen M, Luan Z (2017) Association of folypolyglutamate synthetase (FPGS) gene polymorphism with blood drug concentration as well as adverse reactions of methotrexate in children with acute leukaemia. Biomed Res 28:478\u2013483","journal-title":"Biomed Res"},{"key":"4059_CR75","doi-asserted-by":"publisher","first-page":"175","DOI":"10.2217\/pgs-2016-0158","volume":"18","author":"Y Chen","year":"2017","unstructured":"Chen Y, Zou K, Sun J, Yang Y, Liu G (2017) Are gene polymorphisms related to treatment outcomes of methotrexate in patients with rheumatoid arthritis? A systematic review and meta-analysis. Pharmacogenomics 18:175\u2013195","journal-title":"Pharmacogenomics"},{"key":"4059_CR76","doi-asserted-by":"publisher","first-page":"11844","DOI":"10.1038\/s41598-022-15991-0","volume":"12","author":"HX Sha","year":"2022","unstructured":"Sha HX, Veerapen K, Chow SK, Gun SC, Lau IS, Lim RLH et al (2022) Genetic variations in methotrexate metabolic pathway genes influence methotrexate responses in rheumatoid arthritis patients in Malaysia. Sci Rep 12:11844","journal-title":"Sci Rep"},{"issue":"5","key":"4059_CR77","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1007\/s00280-020-04058-4","volume":"85","author":"L Yang","year":"2020","unstructured":"Yang L, Wu H, de Winter BC, Sheng CC, Qiu HQ, Cheng Y et al (2020) Pharmacokinetics and pharmacogenetics of high-dose methotrexate in Chinese adult patients with non-Hodgkin lymphoma: a population analysis. Cancer Chemother Pharmacol 85(5):881\u2013897","journal-title":"Cancer Chemother Pharmacol"},{"key":"4059_CR78","doi-asserted-by":"publisher","first-page":"136","DOI":"10.3109\/15569543.2015.1083033","volume":"34","author":"A Kalantari","year":"2015","unstructured":"Kalantari A, Zaker F, Ansari S, Sharafi H, Mohammadian M (2015) The effect of polymorphisms of gamma-glutamyl hydrolase (GGH) gene on methotrexate-induced toxicity in acute lymphoblastic leukemia. Toxin Rev 34:136\u2013141","journal-title":"Toxin Rev"},{"key":"4059_CR79","doi-asserted-by":"publisher","first-page":"3461","DOI":"10.7314\/APJCP.2012.13.7.3461","volume":"13","author":"N Koomdee","year":"2012","unstructured":"Koomdee N, Hongeng S, Apibal S, Pakikisama S (2012) Association between polymorphisms of dihydrofolate reductase and gamma glutamyl hydrolase genes and toxicity of high dose methotrexate in children with acute lymphoblastic leukemia. Asian Pac J Cancer Prev 13:3461\u20133464","journal-title":"Asian Pac J Cancer Prev"},{"issue":"2","key":"4059_CR80","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1080\/00498254.2024.2320778","volume":"54","author":"K Shendy","year":"2024","unstructured":"Shendy K, Abdelkawy K, Ali AA, Belal F, Abdelhakiem M, Magdy G et al (2024) The effects of genetic polymorphism on toxicity and pharmacokinetics of methotrexate in Egyptian adult patients with leukaemia or lymphoma. Xenobiotica 54(2):95\u2013105. https:\/\/doi.org\/10.1080\/00498254.2024.2320778","journal-title":"Xenobiotica"},{"issue":"4","key":"4059_CR81","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1691\/ph.2020.9932","volume":"75","author":"M Li","year":"2020","unstructured":"Li M, Wang SM, Wu WS, Yan D, Zhang LP, Zheng HY (2020) Frequency distribution of five SNPs in human GGH gene and their effects on clinical outcomes of Chinese pediatric patients with acute lymphoblastic leukemia. Pharmazie 75(4):142\u2013146. https:\/\/doi.org\/10.1691\/ph.2020.9932","journal-title":"Pharmazie"},{"issue":"11","key":"4059_CR82","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1093\/jpp\/rgab099","volume":"73","author":"Q Zhao","year":"2021","unstructured":"Zhao Q, Cui Y, Zeng C, Ren X, Yu K, Lin S et al (2021) Association between SNPs and hepatotoxicity in patients with primary central nervous system lymphoma on high-dose methotrexate therapy. J Pharm Pharmacol 73(11):1480\u20131490. https:\/\/doi.org\/10.1093\/jpp\/rgab099","journal-title":"J Pharm Pharmacol"},{"issue":"6","key":"4059_CR83","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1111\/jcpt.13505","volume":"46","author":"Y Gong","year":"2021","unstructured":"Gong Y, Luo L, Wang L, Chen J, Chen F, Ma Y et al (2021) Association of MTHFR and ABCB1 polymorphisms with MTX-induced mucositis in Chinese paediatric patients with acute lymphoblastic leukaemia, lymphoma or osteosarcoma - A retrospective cohort study. J Clin Pharm Ther 46(6):1557\u20131563. https:\/\/doi.org\/10.1111\/jcpt.13505","journal-title":"J Clin Pharm Ther"},{"key":"4059_CR84","doi-asserted-by":"publisher","DOI":"10.1038\/srep35615","volume":"6","author":"T Yamamoto","year":"2016","unstructured":"Yamamoto T, Shikano K, Nanki T, Kawai S (2016) Folylpolyglutamate synthase is a major determinant of intracellular methotrexate polyglutamates in patients with rheumatoid arthritis. Sci Rep 6:35615","journal-title":"Sci Rep"},{"key":"4059_CR85","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1038\/s41397-019-0097-x","volume":"20","author":"N Muralidharan","year":"2020","unstructured":"Muralidharan N, Sundaram R, Kodidela S, Chengappa KG, Mariaselvam CM, Misra DP et al (2020) Folyl polyglutamate synthethase (FPGS) gene polymorphisms may influence methotrexate adverse events in South Indian Tamil rheumatoid arthritis patients. Pharmacogenomics J 20:342\u2013349","journal-title":"Pharmacogenomics J"},{"key":"4059_CR86","doi-asserted-by":"publisher","DOI":"10.1186\/s12969-015-0002-3","volume":"13","author":"EHPV van Dijkhuizen","year":"2015","unstructured":"van Dijkhuizen EHPV, Bulatovi\u0107 \u0106alasan M, Pluijm SMF, Rotte MCFJD, Vastert SJ, Kamphuis SSM et al (2015) Prediction of methotrexate intolerance in juvenile idiopathic arthritis: a prospective, observational cohort study. Pediatr Rheumatol Online J 13:5","journal-title":"Pediatr Rheumatol Online J"},{"issue":"6","key":"4059_CR87","doi-asserted-by":"publisher","first-page":"594","DOI":"10.3390\/genes11060594","volume":"11","author":"S Kodidela","year":"2020","unstructured":"Kodidela S, Dorababu P, Thakkar DN, Dubashi B, Sundaram R, Muralidharan N et al (2020) Association of NUDT15 c. 415C\u2009>\u2009T and FPGS 2572C\u2009>\u2009T variants with the risk of early hematologic toxicity during 6-MP and low-dose methotrexate-based maintenance therapy in Indian patients with acute lymphoblastic leukemia. Genes 11(6):594\u00a0","journal-title":"Genes"},{"key":"4059_CR88","doi-asserted-by":"publisher","first-page":"3095","DOI":"10.1002\/art.22129","volume":"54","author":"T Dervieux","year":"2006","unstructured":"Dervieux T, Greenstein N, Kremer J (2006) Pharmacogenomic and metabolic biomarkers in the folate pathway and their association with methotrexate effects during dosage escalation in rheumatoid arthritis. Arthritis Rheumatol 54:3095\u20133103","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"4059_CR89","doi-asserted-by":"publisher","first-page":"164","DOI":"10.2133\/dmpk.DMPK-12-NT-038","volume":"28","author":"H Hayashi","year":"2013","unstructured":"Hayashi H, Tazoe Y, Tsuboi S, Horino M, Morishita M, Arai T et al (2013) A single nucleotide polymorphism of reduced folate carrier 1 predicts methotrexate efficacy in Japanese patients with rheumatoid arthritis. Drug Metab Pharmacokinet 28(2):164\u2013168","journal-title":"Drug Metab Pharmacokinet"},{"key":"4059_CR90","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s40780-016-0047-6","volume":"2","author":"M Hashiguchi","year":"2016","unstructured":"Hashiguchi M, Tsuru T, Miyawaki K, Suzaki M, Hakamata J, Shimizu M et al (2016) Preliminary study for predicting better methotrexate efficacy in Japanese patients with rheumatoid arthritis. J Pharm Health Care Sci 2:13","journal-title":"J Pharm Health Care Sci"},{"key":"4059_CR91","doi-asserted-by":"publisher","first-page":"25","DOI":"10.2217\/pgs.15.150","volume":"17","author":"P Moya","year":"2016","unstructured":"Moya P, Salazar J, Arranz MJ, D\u00edaz-Torn\u00e9 C, del R\u00edo E, Casademont J et al (2016) Methotrexate pharmacokinetic genetic variants are associated with outcome in rheumatoid arthritis patients. Pharmacogenomics 17:25\u201329","journal-title":"Pharmacogenomics"},{"issue":"4","key":"4059_CR92","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1097\/FPC.0000000000000563","volume":"35","author":"SM Wang","year":"2025","unstructured":"Wang SM, Zhao DQ, Kong XY, Li M (2025) The impact of genetic variations in FPGS, MTHFR, and ATIC on methotrexate response among pediatric patients with acute lymphoblastic leukemia. Pharmacogenet Genomics 35(4):127\u2013135\u00a0","journal-title":"Pharmacogenet Genomics"},{"key":"4059_CR93","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s00280-014-2507-8","volume":"74","author":"SM Wang","year":"2014","unstructured":"Wang SM, Sun LL, Zeng WX, Wu WS, Zhang GL (2014) Influence of genetic polymorphisms of FPGS, GGH, and MTHFR on serum methotrexate levels in Chinese children with acute lymphoblastic leukemia. Cancer Chemother Pharmacol 74:283\u2013289\u00a0","journal-title":"Cancer Chemother Pharmacol"},{"key":"4059_CR94","doi-asserted-by":"publisher","first-page":"4967","DOI":"10.12659\/MSM.899021","volume":"22","author":"Z Huang","year":"2016","unstructured":"Huang Z, Tong HF, Li Y, Qian JC, Wang JX, Wang Z et al (2016) Effect of the polymorphism of folylpolyglutamate synthetase on treatment of high-dose methotrexate in pediatric patients with acute lymphocytic leukemia. Med Sci Monit 22:4967","journal-title":"Med Sci Monit"},{"key":"4059_CR95","doi-asserted-by":"publisher","first-page":"177","DOI":"10.17533\/udea.vitae.v22n3a02","volume":"22","author":"F Zaruma-Torres","year":"2015","unstructured":"Zaruma-Torres F, Lares-Asseff I, Reyes-Espinoza A, Loera-Casta\u00f1eda V, Almanza-Reyes H, Arias-Pel\u00e1ez MC (2015) Impacto de polimorfismos gen\u00e9ticos de la v\u00eda metab\u00f3lica del metotrexato sobre la sobrevida de ni\u00f1os mexicanos con leucemia linfobl\u00e1stica aguda (LLA). Vitae 22:177\u2013187","journal-title":"Vitae"},{"issue":"6","key":"4059_CR96","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15061661","volume":"15","author":"FC Ceballos","year":"2023","unstructured":"Ceballos FC, Chamizo-Carmona E, Mata-Mart\u00edn C, Carrasco-Cubero C, Aznar-S\u00e1nchez JJ, Veroz-Gonz\u00e1lez R et al (2023) Pharmacogenetic sex-specific effects of methotrexate response in patients with rheumatoid arthritis. Pharmaceutics 15(6):1661","journal-title":"Pharmaceutics"},{"key":"4059_CR97","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1097\/FPC.0b013e328331b53e","volume":"19","author":"S Sharma","year":"2009","unstructured":"Sharma S, Das M, Kumar A, Marwaha V, Shankar S, Singh P et al (2009) Purine biosynthetic pathway genes and methotrexate response in rheumatoid arthritis patients among north Indians. Pharmacogenet Genomics 19:823\u2013828","journal-title":"Pharmacogenet Genomics"},{"key":"4059_CR98","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.111456","volume":"138","author":"J Gr\u017eelj","year":"2021","unstructured":"Gr\u017eelj J, Mlinari\u010d-Ra\u0161\u010dan I, Marko PB, Marovt M, Gmeiner T, \u0160mid A (2021) Polymorphisms in GNMT and DNMT3b are associated with methotrexate treatment outcome in plaque psoriasis. Biomed Pharmacother 138:111456","journal-title":"Biomed Pharmacother"},{"issue":"12","key":"4059_CR99","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1097\/FPC.0b013e328311a8fd","volume":"18","author":"S Sharma","year":"2008","unstructured":"Sharma S, Das M, Kumar A, Marwaha V, Shankar S, Aneja R et al (2008) Interaction of genes from influx-metabolism-efflux pathway and their influence on methotrexate efficacy in rheumatoid arthritis patients among Indians. Pharmacogenet Genomics 18(12):1041\u20131049","journal-title":"Pharmacogenet Genomics"},{"issue":"15","key":"4059_CR100","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.2217\/pgs-2016-0067","volume":"17","author":"AR Lima","year":"2016","unstructured":"Lima AR, Bernardes M, Azevedo R, Seabra V, Medeiros R (2016) Moving toward personalized medicine in rheumatoid arthritis: SNPs in methotrexate intracellular pathways are associated with methotrexate therapeutic outcome. Pharmacogenomics 17(15):1649\u20131674","journal-title":"Pharmacogenomics"},{"issue":"6","key":"4059_CR101","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.reuma.2016.08.006","volume":"13","author":"L Sala-Icardo","year":"2017","unstructured":"Sala-Icardo L, Lamana A, Ortiz AM, Garc\u00eda Lorenzo E, Moreno Fresneda P, Garc\u00eda-Vicu\u00f1a R et al (2017) Impact of genetic variants of ATP binding cassette B1, AICAR transformylase\/IMP cyclohydrolase, folyl-polyglutamate synthetase, and methylenetetrahydrofolate reductase on methotrexate toxicity. Reumatol Clin 13(6):318\u2013325","journal-title":"Reumatol Clin"},{"issue":"3","key":"4059_CR102","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1111\/j.1365-2710.2009.01046.x","volume":"34","author":"H Hayashi","year":"2009","unstructured":"Hayashi H, Fujimaki C, Daimon T, Tsuboi S, Matsuyama T, Itoh K et al (2009) Genetic polymorphisms in folate pathway enzymes as a possible marker for predicting the outcome of methotrexate therapy in Japanese patients with rheumatoid arthritis. J Clin Pharm Ther 34(3):355\u2013361","journal-title":"J Clin Pharm Ther"},{"key":"4059_CR103","doi-asserted-by":"publisher","first-page":"152036","DOI":"10.1016\/j.semarthrit.2022.152036","volume":"55","author":"J Cui","year":"2022","unstructured":"Cui J, Chasman DI, Raychaudhuri S, Xu C, Ridker PM, Solomon DH et al (2022) Genetics are not likely to offer clinically useful predictions for elevated liver enzyme levels in patients using low dose methotrexate. Semin Arthritis Rheum 55:152036","journal-title":"Semin Arthritis Rheum"},{"key":"4059_CR104","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1097\/FPC.0b013e32833315d1","volume":"19","author":"T Dervieux","year":"2009","unstructured":"Dervieux T, Wessels JA, van der Straaten T, Penrod N, Moore JH, Guchelaar HJ et al (2009) Gene\u2013gene interactions in folate and adenosine biosynthesis pathways affect methotrexate efficacy and tolerability in rheumatoid arthritis. Pharm Genomics 19:935\u2013944","journal-title":"Pharm Genomics"},{"key":"4059_CR105","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.leukres.2009.11.027","volume":"34","author":"J Organista-Nava","year":"2010","unstructured":"Organista-Nava J, G\u00f3mez-G\u00f3mez Y, Saavedra-Herrera MV, Rivera-Ram\u00edrez AB, Ter\u00e1n-Porcayo MA, Alarc\u00f3n-Romero LD et al (2010) Polymorphisms of the \u03b3-glutamyl hydrolase gene and risk of relapse to acute lymphoblastic leukemia in Mexico. Leuk Res 34:728\u2013732","journal-title":"Leuk Res"},{"key":"4059_CR106","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s00228-012-1341-3","volume":"69","author":"B Jekic","year":"2013","unstructured":"Jekic B, Lukovic L, Bunjevacki V, Milic V, Novakovic I, Damnjanovic T et al (2013) Association of the TYMS 3G\/3G genotype with poor response and GGH 354GG genotype with the bone marrow toxicity of the methotrexate in RA patients. Eur J Clin Pharmacol 69:377\u2013383","journal-title":"Eur J Clin Pharmacol"},{"key":"4059_CR107","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/j.leukres.2006.08.007","volume":"31","author":"F Garcia-Bournissen","year":"2007","unstructured":"Garcia-Bournissen F, Moghrabi A, Krajinovic M (2007) Therapeutic responses in childhood acute lymphoblastic leukemia (ALL) and haplotypes of gamma glutamyl hydrolase (GGH) gene. Leuk Res 31:1023\u20131025","journal-title":"Leuk Res"},{"key":"4059_CR108","doi-asserted-by":"publisher","first-page":"303","DOI":"10.3109\/08880018.2012.657767","volume":"29","author":"X Chen","year":"2012","unstructured":"Chen X, Wen F, Yue L, Li C (2012) Genetic polymorphism of \u03b3-glutamyl hydrolase in Chinese acute leukemia children and identification of a novel double nonsynonymous mutation. Pediatr Hematol Oncol 29:303\u2013312","journal-title":"Pediatr Hematol Oncol"},{"issue":"1","key":"4059_CR109","doi-asserted-by":"publisher","first-page":"7342","DOI":"10.1038\/s41598-018-25634-y","volume":"8","author":"R L\u00f3pez-Rodr\u00edguez","year":"2018","unstructured":"L\u00f3pez-Rodr\u00edguez R, Ferreiro-Iglesias A, Lima A, Bernardes M, Pawlik A, Paradowska-Gorycka A et al (2018) Replication study of polymorphisms associated with response to methotrexate in patients with rheumatoid arthritis. Sci rep 8(1):7342","journal-title":"Sci rep"},{"key":"4059_CR110","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.3324\/haematol.2009.008326","volume":"94","author":"A Ongaro","year":"2009","unstructured":"Ongaro A, De Mattei M, Della Porta MG, Rigolin G, Ambrosio C, Di Raimondo F et al (2009) Gene polymorphisms in folate metabolizing enzymes in adult acute lymphoblastic leukemia: effects on methotrexate-related toxicity and survival. Haematologica 94:1391\u20131398","journal-title":"Haematologica"},{"key":"4059_CR111","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.2217\/pgs.14.67","volume":"15","author":"J Salazar","year":"2014","unstructured":"Salazar J, Moya P, Alt\u00e9s A, D\u00edaz-Torn\u00e9 C, Casademont J, Cerd\u00e0-Gabaroi D et al (2014) Polymorphisms in genes involved in the mechanism of action of methotrexate: are they associated with outcome in rheumatoid arthritis patients? Pharmacogenomics 15:1079\u20131090","journal-title":"Pharmacogenomics"},{"key":"4059_CR112","first-page":"227","volume":"13","author":"SA Owen","year":"2013","unstructured":"Owen SA, Hider SL, Martin P, Bruce IN, Barton A, Thomson W (2013) Genetic polymorphisms in key methotrexate pathway genes are associated with response to treatment in rheumatoid arthritis patients. Pharm J 13:227\u2013234","journal-title":"Pharm J"},{"key":"4059_CR113","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1097\/FPC.0000000000000036","volume":"24","author":"S Senapati","year":"2014","unstructured":"Senapati S, Singh S, Das M, Kumar A, Gupta R, Kumar U et al (2014) Genome-wide analysis of methotrexate pharmacogenomics in rheumatoid arthritis shows multiple novel risk variants and leads for TYMS regulation. Pharmacogenet Genomics 24:211\u2013219","journal-title":"Pharmacogenet Genomics"},{"key":"4059_CR114","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.2217\/pgs-2016-0090","volume":"17","author":"B Jekic","year":"2016","unstructured":"Jekic B, Vejnovic D, Milic V, Maksimovic N, Damnjanovic T, Bunjevacki V et al (2016) Association of 63\/91 length polymorphism in the DHFR gene major promoter with toxicity of methotrexate in patients with rheumatoid arthritis. Pharmacogenomics 17:1687\u20131691","journal-title":"Pharmacogenomics"},{"key":"4059_CR115","doi-asserted-by":"publisher","first-page":"3661","DOI":"10.1182\/blood.V124.21.3661.3661","volume":"124","author":"D Biswajit","year":"2014","unstructured":"Biswajit D, Kodidela S, Pradhan SC, Basu D, Prasad R, Gurusamy U (2014) Influence of dihydrofolate reducatse (DHFR) gene polymorphisms on outcome of methotrexate maintenance therapy in patients with acute lymphoblastic leukemia. Blood 124:3661","journal-title":"Blood"},{"key":"4059_CR116","doi-asserted-by":"publisher","first-page":"6931","DOI":"10.1158\/1078-0432.CCR-09-0641","volume":"15","author":"F Al-Shakfa","year":"2009","unstructured":"Al-Shakfa F, Dulucq S, Brukner I, Milacic I, AnsariM, Beaulieu P et al (2009) DNA variants in region for noncoding interfering transcript of dihydrofolate reductase gene and outcome in childhood acute lymphoblastic leukemia. Clin Cancer Res 15:6931\u20136938","journal-title":"Clin Cancer Res"},{"issue":"3","key":"4059_CR117","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1080\/17425255.2019.1563594","volume":"15","author":"D Vejnovi\u0107","year":"2019","unstructured":"Vejnovi\u0107 D, Mili\u0107 V, Popovi\u0107 B, Damnjanovi\u0107 T, Maksimovi\u0107 N, Bunjeva\u010dki V et al (2019) Association of C35T polymorphism in dihydrofolate reductase gene with toxicity of methotrexate in rheumatoid arthritis patients. Expert Opin Drug Metab Toxicol 15(3):253\u2013257","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"4059_CR118","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1247\/csf.20.191","volume":"20","author":"N Horie","year":"1995","unstructured":"Horie N, Aiba H, Oguro K, Hojo H, Takeishi K (1995) Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5\u2019-terminal regulatory region of the human gene for thymidylate synthase. Cell Struct Funct 20:191\u2013197","journal-title":"Cell Struct Funct"},{"issue":"5","key":"4059_CR119","doi-asserted-by":"publisher","first-page":"337","DOI":"10.2217\/pgs-2019-0186","volume":"21","author":"JK Sundbaum","year":"2020","unstructured":"Sundbaum JK, Baecklund E, Eriksson N, Hallberg P, Kohnke H, Wadelius M (2020) MTHFR, TYMS and SLCO1B1 polymorphisms and adverse liver effects of methotrexate in rheumatoid arthritis. Pharmacogenomics 21(5):337\u2013346","journal-title":"Pharmacogenomics"},{"key":"4059_CR120","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1007\/s10067-017-3608-7","volume":"36","author":"N Muralidharan","year":"2017","unstructured":"Muralidharan N, Misra DP, Jain VK, Negi VS (2017) Effect of thymidylate synthase (TYMS) gene polymorphisms with methotrexate treatment outcome in south Indian Tamil patients with rheumatoid arthritis. Clin Rheumatol 36:1253\u20131259","journal-title":"Clin Rheumatol"},{"key":"4059_CR121","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0108165","volume":"9","author":"A Lima","year":"2014","unstructured":"Lima A, Seabra V, Bernardes M, Azevedo R, Sousa H, Medeiros R (2014) Role of key TYMS polymorphisms on methotrexate therapeutic outcome in portuguese rheumatoid arthritis patients. PLoS One 9:e108165. https:\/\/doi.org\/10.1371\/journal.pone.0108165","journal-title":"PLoS One"},{"key":"4059_CR122","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.01390","volume":"9","author":"S Lv","year":"2018","unstructured":"Lv S, Fan H, Li J, Yang H, Huang J, Shu XM et al (2018) Genetic polymorphisms of TYMS, MTHFR, ATIC, MTR, and MTRR are related to the outcome of methotrexate therapy for rheumatoid arthritis in a Chinese population. Front Pharmacol 9:1390","journal-title":"Front Pharmacol"},{"key":"4059_CR123","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.00020","volume":"9","author":"B Jenko","year":"2018","unstructured":"Jenko B, Tomsic M, Praprotnik S, Jekic B, Milic V, Dolzan V (2018) Clinical pharmacogenetic models of treatment response to methotrexate monotherapy in Slovenian and Serbian rheumatoid arthritis patients: differences in patient\u2019s management may preclude generalization of the models. Front Pharmacol 9:20","journal-title":"Front Pharmacol"},{"key":"4059_CR124","doi-asserted-by":"publisher","first-page":"5153","DOI":"10.1182\/blood-2013-01-480335","volume":"121","author":"S Radtke","year":"2013","unstructured":"Radtke S, Zolk O, Renner B, Paulides M, Zimmermann M, Moricke A et al (2013) Germline genetic variations in methotrexate candidate genes are associated with pharmacokinetics, toxicity, and outcome in childhood acute lymphoblastic leukemia. Blood 121:5153\u20135154","journal-title":"Blood"},{"key":"4059_CR125","first-page":"412","volume":"17","author":"B Jenko","year":"2016","unstructured":"Jenko B, Lusa L, Tomsic M, Praprotnik S, Dolzan V (2016) Clinical\u2013pharmacogenetic predictive models for MTX discontinuation due to adverse events in rheumatoid arthritis. Pharm J 17:412\u2013418","journal-title":"Pharm J"},{"key":"4059_CR126","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s13318-015-0288-z","volume":"41","author":"S Chaabane","year":"2016","unstructured":"Chaabane S, Marzouk S, Akrout R, Hamad MB, Achour Y, Rebai A et al (2016) Genetic determinants of methotrexate toxicity in Tunisian patients with rheumatoid arthritis: a study of polymorphisms involved in the MTX metabolic pathway. Eur J Drug Metab Pharmacokinet 41:385\u2013393","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"4059_CR127","first-page":"593","volume":"11","author":"K Kumagai","year":"2003","unstructured":"Kumagai K, Hiyama K, Oyama T, Maeda H, Kohno N (2003) Polymorphisms in the thymidylate synthase and methylenetetrahydrofolate reductase genes and sensitivity to the low-dose methotrexate therapy in patients with rheumatoid arthritis. Int J Mol Med 11:593\u2013600","journal-title":"Int J Mol Med"},{"key":"4059_CR128","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1097\/FPC.0000000000000069","volume":"24","author":"NK Zgheib","year":"2014","unstructured":"Zgheib NK, Akra-Ismail M, Aridi C, Mahfouz R, Abboud MR, Solh H et al (2014) Genetic polymorphisms in candidate genes predict increased toxicity with methotrexate therapy in Lebanese children with acute lymphoblastic leukemia. Pharmacogenet Genomics 24:387\u2013396","journal-title":"Pharmacogenet Genomics"},{"key":"4059_CR129","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.3109\/10428194.2011.639880","volume":"53","author":"N Er\u010dulj","year":"2012","unstructured":"Er\u010dulj N, Kotnik BF, Debeljak M, Jazbec J, Dol\u017ean V (2012) Influence of folate pathway polymorphisms on high-dose methotrexaterelated toxicity and survival in childhood acute lymphoblastic leukemia. Leuk Lymphoma 53:1096\u20131104","journal-title":"Leuk Lymphoma"},{"key":"4059_CR130","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1038\/sj.tpj.6500332","volume":"5","author":"M Krajinovic","year":"2005","unstructured":"Krajinovic M, Costea I, Primeau M, Dulucq S, Moghrabi A (2005) Combining several polymorphisms of thymidylate synthase gene for pharmacogenetic analysis. Pharmacogenomics J 5:374\u2013380","journal-title":"Pharmacogenomics J"},{"key":"4059_CR131","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1016\/j.leukres.2011.04.007","volume":"35","author":"JJ Pietrzyk","year":"2011","unstructured":"Pietrzyk JJ, Bik-Multanowski M, Skoczen S, Kowalczyk J, Balwierz W, Matysiak M et al (2011) Polymorphism of the thymidylate synthase gene and risk of relapse in childhood ALL. Leuk Res 35:1464\u20131466","journal-title":"Leuk Res"},{"issue":"3","key":"4059_CR132","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0091261","volume":"9","author":"E L\u00f3pez-L\u00f3pez","year":"2014","unstructured":"L\u00f3pez-L\u00f3pez E, Guti\u00e9rrez-Camino \u00c1, Pi\u00f1\u00e1n M\u00c1, S\u00e1nchez-Toledo J, Uriz JJ, Ballesteros J et al (2014) Pharmacogenetics of microRNAs and microRNAs biogenesis machinery in pediatric acute lymphoblastic leukemia. PLoS One 9(3):e91261. https:\/\/doi.org\/10.1371\/journal.pone.0091261","journal-title":"PLoS One"},{"key":"4059_CR133","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2023.1153767","volume":"11","author":"M Zhan","year":"2023","unstructured":"Zhan M, Liu T, Zhang Z, Wang G, Cao Z, Li X, Zeng H, Mai H, Chen Z (2023) Impact of microRNA polymorphisms on high-dose methotrexate-related hematological toxicities in pediatric acute lymphoblastic leukemia. Front Pediatr 11:1153767. https:\/\/doi.org\/10.3389\/fped.2023.1153767","journal-title":"Front Pediatr"},{"issue":"8","key":"4059_CR134","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1097\/FPC.0000000000000291","volume":"27","author":"A Gutierrez-Camino","year":"2017","unstructured":"Gutierrez-Camino A, Oosterom N, den Hoed MAH, Lopez-Lopez E, Martin-Guerrero I, Pluijm SMF, Pieters R, de Jonge R, Tissing WJE, Heil SG, Garc\u00eda-Orad A, van den Heuvel-Eibrink MM (2017) The miR-1206 microRNA variant is associated with methotrexate-induced oral mucositis in pediatric acute lymphoblastic leukemia. Pharmacogenet Genomics 27(8):303\u2013306","journal-title":"Pharmacogenet Genomics"},{"key":"4059_CR135","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2017.e00467","volume":"3","author":"LM Berkani","year":"2017","unstructured":"Berkani LM, Rahal F, Allam I, Benani SM, Laadjouz A, Djidjik R (2017) Association of MTHFR C677T and A1298C gene polymorphisms with methotrexate efficiency and toxicity in Algerian rheumatoid arthritis patients. Heliyon 3:e00467","journal-title":"Heliyon"},{"key":"4059_CR136","doi-asserted-by":"publisher","first-page":"539","DOI":"10.3899\/jrheum.080576","volume":"36","author":"MC Fisher","year":"2009","unstructured":"Fisher MC, Cronstein BN (2009) Metaanalysis of methylenetetrahydrofolate reductase (MTHFR) polymorphisms affecting methotrexate toxicity. J Rheumatol 36:539\u2013545","journal-title":"J Rheumatol"},{"key":"4059_CR137","doi-asserted-by":"publisher","first-page":"869912","DOI":"10.3389\/fmed.2022.869912","volume":"9","author":"J Zhu","year":"2022","unstructured":"Zhu J, Wang Z, Tao L, Han L, Huang Q, Fang et al (2022) MTHFR gene polymorphism association with psoriatic arthritis risk and the efficacy and hepatotoxicity of methotrexate in psoriasis. Front Med 9:869912","journal-title":"Front Med"},{"issue":"6","key":"4059_CR138","doi-asserted-by":"publisher","first-page":"529","DOI":"10.2217\/pgs-2017-0208","volume":"19","author":"Y Chen","year":"2018","unstructured":"Chen Y, Zou K, Sun J, Yang Y, Liu G (2018) Associations between gene polymorphisms and treatment outcomes of methotrexate in patients with juvenile idiopathic arthritis. Pharmacogenomics 19(6):529\u2013538","journal-title":"Pharmacogenomics"},{"issue":"3","key":"4059_CR139","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/tpj.2017.34","volume":"18","author":"C Zhu","year":"2017","unstructured":"Zhu C, Liu YW, Wang SZ, Li XL, Nie X, Yu XT et al (2017) Associations between the C677T and A1298C polymorphisms of MTHFR and the toxicity of methotrexate in childhood malignancies: a meta-analysis. Pharm J 18(3):450\u2013459. https:\/\/doi.org\/10.1038\/tpj.2017.34","journal-title":"Pharm J"},{"key":"4059_CR140","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.2217\/pgs-2016-0004","volume":"17","author":"M Zhao","year":"2016","unstructured":"Zhao M, Liang L, Ji L, Chen D, Zhang Y, Zhu Y et al (2016) MTHFR gene polymorphisms and methotrexate toxicity in adult patients with hematological malignancies: a meta-analysis. Pharmacogenomics 17:1005\u20131017","journal-title":"Pharmacogenomics"},{"issue":"2","key":"4059_CR141","doi-asserted-by":"publisher","first-page":"e58","DOI":"10.1016\/j.clml.2019.11.020","volume":"20","author":"FT Zahra","year":"2020","unstructured":"Zahra FT, Nahid NA, Islam MR, Al-Mamun MMA, Apu MNH, Nahar Z et al (2020) Pharmacogenetic variants in MTHFR gene are significant predictors of methotrexate toxicities in Bangladeshi patients with acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk 20(2):e58\u2013e65","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"4059_CR142","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1007\/s10067-014-2645-8","volume":"33","author":"GG Song","year":"2014","unstructured":"Song GG, Bae SC, Lee YH (2014) Association of the MTHFR C677T and A1298C polymorphisms with methotrexate toxicity in rheumatoid arthritis: a meta-analysis. Clin Rheumatol 33:1715\u20131724","journal-title":"Clin Rheumatol"},{"key":"4059_CR143","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1111\/ejh.12302","volume":"93","author":"MW Ayad","year":"2014","unstructured":"Ayad MW, El Naggar AA, El Naggar M (2014) MTHFR C677T polymorphism: association with lymphoid neoplasm and effect on methotrexate therapy. Eur J Haematol 93:63\u201369","journal-title":"Eur J Haematol"},{"issue":"5","key":"4059_CR144","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1007\/s13277-012-0395-2","volume":"33","author":"L Yang","year":"2012","unstructured":"Yang L, Hu X, Xu L (2012) Impact of methylenetetrahydrofolate reductase (MTHFR) polymorphisms on methotrexate-induced toxicities in acute lymphoblastic leukemia: a meta-analysis. Tumour Biol 33(5):1445\u20131454","journal-title":"Tumour Biol"},{"key":"4059_CR145","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1182\/blood.V98.1.231","volume":"98","author":"CM Ulrich","year":"2001","unstructured":"Ulrich CM, Yasui Y, Storb R, Schubert MM, Wagner JL, Bigler J et al (2001) Pharmacogenetics of methotrexate: toxicity among marrow transplantation patients varies with the methylenetetrahydrofolate reductase C677T polymorphism. Blood 98:231\u2013234","journal-title":"Blood"},{"issue":"5","key":"4059_CR146","doi-asserted-by":"publisher","first-page":"585","DOI":"10.3390\/pharmaceutics17050585","volume":"17","author":"LM Marangoni-Iglecias","year":"2025","unstructured":"Marangoni-Iglecias LM, S\u00e1nchez-Martin A, Pineda-Lancheros LE, Cura Y, Marquez-Pete N, G\u00e1lvez-Navas JM et al (2025) Impact of Pharmacogenetics on High-Dose Methotrexate Toxicity in Pediatric Oncology. Pharmaceutics 17(5):585","journal-title":"Pharmaceutics"},{"issue":"10","key":"4059_CR147","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24108538","volume":"24","author":"M Jelovac","year":"2023","unstructured":"Jelovac M, Kotur N, Ristivojevic B, Pavlovic D, Spasovski V, Damjanov N et al (2023) Can pharmacogenetic variants in TPMT, MTHFR and SLCO1B1 genes be used as potential markers of outcome prediction in systemic sclerosis patients? Int J Mol Sci 24(10):8538","journal-title":"Int J Mol Sci"},{"key":"4059_CR148","doi-asserted-by":"publisher","first-page":"4926","DOI":"10.1182\/blood.V122.21.4926.4926","volume":"122","author":"NK Zgheib","year":"2013","unstructured":"Zgheib NK, Akra-Ismail M, Aridi C, Mahfouz R, Saab R, Abboud MR et al (2013) Genetic polymorphisms in candidate genes predict increased toxicity with methotrexate therapy in children with acute lymphoblastic leukemia in Lebanon. Blood 122:4926","journal-title":"Blood"},{"key":"4059_CR149","doi-asserted-by":"publisher","first-page":"467","DOI":"10.2217\/pgs.13.235","volume":"15","author":"MD Morgan","year":"2014","unstructured":"Morgan MD, AlShaarawy N, Martin S, Robinson JI, Twigg S, YEAR Consortium et al (2014) MTHFR functional genetic variation and methotrexate treatment response in rheumatoid arthritis: a metaanalysis. Pharmacogenomics 15:467\u2013475","journal-title":"Pharmacogenomics"},{"key":"4059_CR150","first-page":"407","volume":"16","author":"Q Zhang","year":"2023","unstructured":"Zhang Q, Fu P, Cao Z, Huang H, Wen Q, Wang K et al (2023) MTHFR and MTRR genetic polymorphism of methotrexate therapy outcomes in early rheumatoid arthritis. Pharmacogenomics Pers Med 16:407\u2013423","journal-title":"Pharmacogenomics Pers Med"},{"key":"4059_CR151","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.1075603","volume":"13","author":"SS Kolan","year":"2022","unstructured":"Kolan SS, Li G, Grimolizzi F, Sexton J, Goll G, Kvien TK et al (2022) Identification of SNPs associated with methotrexate treatment outcomes in patients with early rheumatoid arthritis. Front Pharmacol 13:1075603","journal-title":"Front Pharmacol"},{"key":"4059_CR152","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1136\/ard.2005.046797","volume":"65","author":"LB Hughes","year":"2006","unstructured":"Hughes LB, Beasley TM, Patel H, Tiwari HK, Morgan SL, Baggott JE et al (2006) Racial or ethnic differences in allele frequencies of single-nucleotide polymorphisms in the methylenetetrahydrofolate reductase gene and their influence on response to methotrexate in rheumatoid arthritis. Ann Rheum Dis 65:1213\u20131218","journal-title":"Ann Rheum Dis"},{"key":"4059_CR153","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1002\/art.21726","volume":"54","author":"JA Wessels","year":"2006","unstructured":"Wessels JA, de Vries-Bouwstra JK, Heijmans BT, Slagboom PE, Goekoop\u2010Ruiterman YP, Allaart CF et al (2006) Efficacy and toxicity of methotrexate in early rheumatoid arthritis are associated with single\u2010nucleotide polymorphisms in genes coding for folate pathway enzymes. Arthritis Rheum 54:1087\u20131095","journal-title":"Arthritis Rheum"},{"key":"4059_CR154","first-page":"287","volume":"11","author":"JP Mena","year":"2011","unstructured":"Mena JP, Salazar-Paramo M, Gonzalez-Lopez L, Gamez-Nava JI, Sandoval-Ramirez L, Sanchez JD et al (2011) Polymorphisms C677T and A1298C in the MTHFR gene in Mexican patients with rheumatoid arthritis treated with methotrexate: implication with elevation of transaminases. Pharm J 11:287\u2013291","journal-title":"Pharm J"},{"key":"4059_CR155","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1097\/00008571-200204000-00002","volume":"12","author":"W Urano","year":"2002","unstructured":"Urano W, Taniguchi A, Yamanaka H, Tanaka E, Nakajima H, Matsuda Y et al (2002) Polymorphisms in the methylenetetrahydrofolate reductase gene were associated with both the efficacy and the toxicity of methotrexate used for the treatment of rheumatoid arthritis, as evidenced by single locus and haplotype analyses. Pharmacogenetics 12:183\u2013190","journal-title":"Pharmacogenetics"},{"key":"4059_CR156","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1136\/ard.2003.016337","volume":"63","author":"Y Berkun","year":"2004","unstructured":"Berkun Y, Levartovsky D, Rubinow A, Orbach H, Aamar S, Grenader T et al (2004) Methotrexate related adverse effects in patients with rheumatoid arthritis are associated with the A1298C polymorphism of the MTHFR gene. Ann Rheum Dis 63:1227\u20131231","journal-title":"Ann Rheum Dis"},{"key":"4059_CR157","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1007\/s00277-007-0274-x","volume":"86","author":"S Pakakasama","year":"2007","unstructured":"Pakakasama S, Kanchanakamhaeng K, Kajanachumpol S, Udomsubpayakul U, Sirachainan N, Thithapandha A et al (2007) Genetic polymorphisms of folate metabolic enzymes and toxicities of high dose methotrexate in children with acute lymphoblastic leukemia. Ann Hematol 86:609\u2013611","journal-title":"Ann Hematol"},{"key":"4059_CR158","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1093\/annonc\/mdf322","volume":"13","author":"P Chiusolo","year":"2002","unstructured":"Chiusolo P, Reddiconto G, Casorelli I, Laurenti L, Sora F, Mele L et al (2002) Preponderance of methylenetetrahydrofolate reductase C677T homozygosity among leukemia patients intolerant to methotrexate. Ann Oncol 13:1915\u20131918\u00a0","journal-title":"Ann Oncol"},{"key":"4059_CR159","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.2217\/14622416.8.11.1551","volume":"8","author":"M Kurzawski","year":"2007","unstructured":"Kurzawski M, Pawlik A, Safranow K, Herczynska M, Drozdzik M (2007) 677C\u2009>\u2009T and 1298A\u2009>\u2009C MTHFR polymorphisms affect methotrexate treatment outcome in rheumatoid arthritis. Pharmacogenomics 8:1551\u20131559","journal-title":"Pharmacogenomics"},{"key":"4059_CR160","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1097\/MBC.0b013e32835b249d","volume":"24","author":"DS Eissa","year":"2013","unstructured":"Eissa DS, Ahmed TM (2013) C677T and A1298C polymorphisms of the methylenetetrahydrofolate reductase gene: effect on methotrexate-related toxicity in adult acute lymphoblastic leukaemia. Blood Coagul Fibrinolysis 24:181\u2013188","journal-title":"Blood Coagul Fibrinolysis"},{"key":"4059_CR161","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1200\/JCO.2004.05.147","volume":"22","author":"K Robien","year":"2004","unstructured":"Robien K, Schubert MM, Bruemmer B, Lloid ME, Potter JD, Ulrich CM (2004) Predictors of oral mucositis in patients receiving hematopoietic stem cell transplants for chronic myelogenous leukemia. J Clin Oncol 22:1268\u20131275","journal-title":"J Clin Oncol"},{"issue":"1","key":"4059_CR162","doi-asserted-by":"publisher","first-page":"15119","DOI":"10.1038\/s41598-024-65199-7","volume":"14","author":"QM Mutlak","year":"2024","unstructured":"Mutlak QM, Kasim AA (2024) Impact of MTHFR gene polymorphism on the outcome of methotrexate treatment in a sample of Iraqi rheumatoid arthritis patients. Sci Rep 14(1):15119","journal-title":"Sci Rep"},{"issue":"6","key":"4059_CR163","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1080\/1120009X.2021.2009723","volume":"34","author":"AIM Ebid","year":"2022","unstructured":"Ebid AIM, Hossam A, El Gammal MM, Soror S, Mangoud NO, Mahmoud MA et al (2022) High dose methotrexate in adult Egyptian patients with hematological malignancies: impact of ABCB1 3435C\u2009>\u2009T rs1045642 and MTHFR 677C\u2009>\u2009T rs1801133 polymorphisms on toxicities and delayed elimination. J Chemother 34(6):381\u2013390","journal-title":"J Chemother"},{"issue":"12","key":"4059_CR164","doi-asserted-by":"publisher","first-page":"2639","DOI":"10.3109\/10428194.2013.784758","volume":"54","author":"V D\u2019Angelo","year":"2013","unstructured":"D\u2019Angelo V, Ramaglia M, Iannotta A, Francese M, Pota E, Affinita MC et al (2013) Influence of methylenetetrahydrofolate reductase gene polymorphisms on the outcome of pediatric patients with non-Hodgkin lymphoma treated with high-dose methotrexate. Leuk Lymphoma 54(12):2639\u20132644","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"4059_CR165","doi-asserted-by":"publisher","first-page":"238528","DOI":"10.1155\/2013\/238528","volume":"2013","author":"H Fukushima","year":"2013","unstructured":"Fukushima H, Fukushima T, Sakai A, Suzuki R, Nakajima- Yamaguchi R, Kobayashi C et al (2013) Polymorphisms of MTHFR associated with higher relapse\/death ratio and delayed weekly MTX administration in pediatric lymphoid malignancies. Leuk Res Treat 2013(1):238528. https:\/\/doi.org\/10.1155\/2013\/238528","journal-title":"Leuk Res Treat"},{"issue":"3","key":"4059_CR166","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1080\/08880018.2019.1705949","volume":"37","author":"RH Razali","year":"2020","unstructured":"Razali RH, Noorizhab MNF, Jamari H, James RJ, Teh KH, Ibrahim HM et al (2020) Association of ABCC2 with levels and toxicity of methotrexate in Malaysian Childhood Acute Lymphoblastic Leukemia (ALL). Pediatr Hematol Oncol 37(3):185\u2013197","journal-title":"Pediatr Hematol Oncol"},{"key":"4059_CR167","doi-asserted-by":"publisher","first-page":"239","DOI":"10.2298\/ABS160325091L","volume":"69","author":"J Lazi\u0107","year":"2017","unstructured":"Lazi\u0107 J, Kotur N, Krstovski N, Dokmanovi\u0107 L, Zuki\u0107 B, Predojevi\u0107-Samard\u017ei\u0107 J et al (2017) Importance of pharmacogenetic markers in the methylenetetrahydrofolate reductase gene during methotrexate treatment in pediatric patients with acute lymphoblastic leukemia. Arch Biol Sci 69:239\u2013246","journal-title":"Arch Biol Sci"},{"key":"4059_CR168","first-page":"238","volume":"4","author":"M \u0106wikli\u0144ska","year":"2014","unstructured":"\u0106wikli\u0144ska M, Balwierz W, Bik-Multanowski M, Klekawka T (2014) 677C\u2009>\u2009T 5, 10-methylenetetrahydrofolate reductase reductase (MTHFR) polymorphism and early toxicity of high-dose methotrexate in children treated for acute lymphoblastic leukemia. Post Nauk Med 4:238\u2013244","journal-title":"Post Nauk Med"},{"issue":"7","key":"4059_CR169","doi-asserted-by":"publisher","first-page":"592","DOI":"10.2174\/1389200220666190701094756","volume":"20","author":"Z Wang","year":"2019","unstructured":"Wang Z, Zhang N, Chen C, Chen S, Xu J, Zhou Y et al (2019) Influence of the OATP polymorphism on the population pharmacokinetics of methotrexate in Chinese patients. Curr Drug Metab 20(7):592\u2013600","journal-title":"Curr Drug Metab"},{"key":"4059_CR170","first-page":"66","volume":"4","author":"M Krajinovic","year":"2004","unstructured":"Krajinovic M, Lemieux-Blanchard E, Chiasson S, Primeau M, Costea I, Moghrab A (2004) Role of polymorphisms in MTHFR and MTHFD1 genes in the outcome of childhood acute lymphoblastic leukemia. Pharm J 4:66\u201372","journal-title":"Pharm J"},{"key":"4059_CR171","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.ejphar.2015.10.058","volume":"769","author":"E Ka\u0142u\u017cna","year":"2015","unstructured":"Ka\u0142u\u017cna E, Strauss E, Zaj\u0105c-Spycha\u0142a O, Gowin E, \u015awi\u0105tek- Ko\u015bcielna B, Nowak J et al (2015) Functional variants of gene encoding folate metabolizing enzyme and methotrexate-related toxicity in children with acute lymphoblastic leukemia. Eur J Pharmacol 769:93\u201399","journal-title":"Eur J Pharmacol"},{"issue":"8","key":"4059_CR172","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1136\/ard.2008.096891","volume":"68","author":"WM Kooloos","year":"2009","unstructured":"Kooloos WM, Wessels JAM, Van Der Kooij SM, Allaart CF, Huizinga TWJ, Guchelaar HJ (2009) Optimisation of the clinical pharmacogenetic model to predict methotrexate treatment response: the influence of the number of haplotypes of MTHFR 1298A\u2013677C alleles on probability to respond. Ann Rheum Dis 68:1371","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"4059_CR173","doi-asserted-by":"publisher","DOI":"10.3390\/jpm10040149","volume":"10","author":"LG D\u2019Cruz","year":"2020","unstructured":"D\u2019Cruz LG, McEleney KG, Tan KB, Shukla P, Gardiner PV, Connolly P et al (2020) Clinical and laboratory associations with methotrexate metabolism gene polymorphisms in rheumatoid arthritis. J Pers Med 10(4):149","journal-title":"J Pers Med"},{"key":"4059_CR174","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1097\/FPC.0b013e3283398a71","volume":"20","author":"LK Stamp","year":"2010","unstructured":"Stamp LK, Chapman PT, O\u2019Donnell JL, Zhang M, James J, Frampton C et al (2010) Polymorphisms within the folate pathway predict folate concentrations but are not associated with disease activity in rheumatoid arthritis patients on methotrexate. Pharm Genomics 20:367\u2013376","journal-title":"Pharm Genomics"},{"key":"4059_CR175","doi-asserted-by":"publisher","first-page":"395","DOI":"10.2298\/GENSR1601395V","volume":"48","author":"D Vejnovic","year":"2016","unstructured":"Vejnovic D, Milic V, Damnjanovic T, Maksimovic N, Bunjevacki V, Lukovic L et al (2016) Analysis of association between polymorphisms of MTHFR, MTHFD1 and RFC1 genes and efficacy and toxicity of methotrexate in rheumatoid arthritis patients. Genetika 48:395\u2013408","journal-title":"Genetika"},{"key":"4059_CR176","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2023.152337","volume":"64","author":"YH Lee","year":"2024","unstructured":"Lee YH, Song GG (2024) A meta-analysis of the association between the ATIC 347 C\/G polymorphism and methotrexate responsiveness and toxicity in rheumatoid arthritis. Semin Arthritis Rheum 64:152337","journal-title":"Semin Arthritis Rheum"},{"key":"4059_CR177","doi-asserted-by":"publisher","unstructured":"Hakamata J, Hashiguchi M, Kaneko Y, Yamaoka K, Shimizu M, Maruyama J et al (2017) Risk factors for abnormal hepatic enzyme elevation by methotrexate treatment in patients with rheumatoid arthritis: a hospital based-cohort study. Mod Rheumatol 1\u201327. https:\/\/doi.org\/10.1080\/14397595.2017.1414765","DOI":"10.1080\/14397595.2017.1414765"},{"key":"4059_CR178","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1007\/s00296-016-3523-2","volume":"36","author":"YH Lee","year":"2016","unstructured":"Lee YH, Bae SC (2016) Association of the ATIC 347 C\/G polymorphism with responsiveness to and toxicity of methotrexate in rheumatoid arthritis: a meta-analysis. Rheumatol Int 36:1591\u20131599","journal-title":"Rheumatol Int"},{"key":"4059_CR179","doi-asserted-by":"publisher","first-page":"241","DOI":"10.2217\/pgs.15.170","volume":"17","author":"N Muralidharan","year":"2016","unstructured":"Muralidharan N, Mariaselvam CM, Jain VK, Gulati R, Negi VS (2016) ATIC 347C\u2009>\u2009G gene polymorphism may be associated with methotrexate-induced adverse events in south Indian Tamil rheumatoid arthritis. Pharmacogenomics 17:241\u2013248","journal-title":"Pharmacogenomics"},{"key":"4059_CR180","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.2217\/pgs-2016-0125","volume":"17","author":"M Kurzawski","year":"2016","unstructured":"Kurzawski M, Malinowski D, Szarmach N, Nowak A, Goryniak A, Pawlik A et al (2016) ATIC missense variant affects response to methotrexate treatment in rheumatoid arthritis patients. Pharmacogenomics 17:1971\u20131978","journal-title":"Pharmacogenomics"},{"issue":"5","key":"4059_CR181","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1111\/1756-185X.14100","volume":"24","author":"A Singh","year":"2021","unstructured":"Singh A, Gangadharan H, Gupta V, Patro PS, Misra R, Aggarwal A (2021) Polymorphism of genes involved in methotrexate pathway: predictors of response to methotrexate therapy in Indian rheumatoid arthritis patients. Int J Rheum Dis 24(5):654\u2013662","journal-title":"Int J Rheum Dis"},{"key":"4059_CR182","doi-asserted-by":"crossref","unstructured":"Wang M, Wen Q, Yu H, Wu X, Zhi S, Cen H (2025) Target gene polymorphisms and clinical response to methotrexate in Chinese rheumatoid arthritis patients. Clin Lab 71(8)","DOI":"10.7754\/Clin.Lab.2025.241250"},{"key":"4059_CR183","first-page":"1","volume":"00","author":"J Roszkiewicz","year":"2020","unstructured":"Roszkiewicz J, Micha\u0142ek D, Ryk A, Swacha Z, Szmyd B, Smolewska E (2020) The impact of single nucleotide polymorphisms in ADORA2A and ADORA3 genes on the early response to methotrexate and presence of therapy side effects in children with juvenile idiopathic arthritis: results of a preliminary study. Int J Rheum Dis 00:1\u20139","journal-title":"Int J Rheum Dis"},{"issue":"5","key":"4059_CR184","first-page":"333","volume":"21","author":"N Kobold","year":"2019","unstructured":"Kobold N, Jenko B, Tom\u0161i\u010d M, Dol\u017ean V, Praprotnik S (2019) ADORA2A polymorphisms influence methotrexate adverse events in rheumatoid arthritis. Isr Med Assoc J 21(5):333\u2013338","journal-title":"Isr Med Assoc J"},{"issue":"8","key":"4059_CR185","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1093\/rheumatology\/ken182","volume":"47","author":"SL Hider","year":"2008","unstructured":"Hider SL, Thomson W, Mack LF, Armstrong DJ, Shadforth M, Bruce IN (2008) Polymorphisms within the adenosine receptor 2a gene are associated with adverse events in RA patients treated with MTX. Rheumatology (Oxford) 47(8):1156\u20131159","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"4059_CR186","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1038\/s41397-020-0168-z","volume":"20","author":"M Grk","year":"2020","unstructured":"Grk M, Milic V, Dolzan V, Maksimovic N, Damnjanovic T, Pjevic MD et al (2020) Analysis of association of ADORA 2 A and ADORA 3 polymorphisms genotypes\/haplotypes with efficacy and toxicity of methotrexate in patients with Rheumatoid arthritis. Pharmacogenomics J 20(6):784\u2013791","journal-title":"Pharmacogenomics J"},{"issue":"2","key":"4059_CR187","doi-asserted-by":"publisher","DOI":"10.1111\/cts.70136","volume":"18","author":"S Braidotti","year":"2025","unstructured":"Braidotti S, Zudeh G, Franca R, Kiren V, Colombini A, Bettini LR et al (2025) The role of candidate polymorphisms in drug transporter genes on high-dose methotrexate in the consolidation phase of the AIEOP\u2010BFM ALL 2009 protocol. Clin Transl Sci 18(2):e70136","journal-title":"Clin Transl Sci"},{"key":"4059_CR188","doi-asserted-by":"publisher","first-page":"192","DOI":"10.2133\/dmpk.DMPK-11-RG-066","volume":"27","author":"T Kato","year":"2012","unstructured":"Kato T, Hamada A, Mori S, Saito H (2012) Genetic polymorphisms in metabolic and cellular transport pathway of methotrexate impact clinical outcome of methotrexate monotherapy in Japanese patients with rheumatoid arthritis. Drug Metab Pharmacokinet 27:192\u2013199","journal-title":"Drug Metab Pharmacokinet"},{"key":"4059_CR189","first-page":"546","volume":"24","author":"R Takatori","year":"2006","unstructured":"Takatori R, Takahashi KA, Tokunaga D, Hojo T, Fujioka M, Asano T et al (2006) ABCB1 C3435T polymorphism influences methotrexate sensitivity in rheumatoid arthritis patients. Clin Exp Rheumatol 24:546\u2013554","journal-title":"Clin Exp Rheumatol"},{"issue":"5","key":"4059_CR190","doi-asserted-by":"publisher","first-page":"381","DOI":"10.2217\/pgs-2018-0172","volume":"20","author":"X He","year":"2019","unstructured":"He X, Sun M, Liang S, Li M, Li L, Yang Y (2019) Association between ABCB1 C3435T polymorphism and methotrexate treatment outcomes in rheumatoid arthritis patients: a meta-analysis. Pharmacogenomics 20(5):381\u2013392","journal-title":"Pharmacogenomics"},{"key":"4059_CR191","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.2217\/pgs.14.97","volume":"15","author":"S Suthandiram","year":"2014","unstructured":"Suthandiram S, Gan GG, Zain SM, Bee PC, Lian LH, Chang KM et al (2014) Effect of polymorphisms within methotrexate pathway genes on methotrexate toxicity and plasma levels in adults with hematological malignancies. Pharmacogenomics 15:1479\u20131494","journal-title":"Pharmacogenomics"},{"issue":"1","key":"4059_CR192","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/phar.4638","volume":"45","author":"RD Harris","year":"2025","unstructured":"Harris RD, Taylor OA, Gramatges MM, Hughes AE, Zobeck M, Pruitt S et al (2025) Evaluation of methotrexate pharmacogenomic variation to predict acute neurotoxicity in children with acute lymphoblastic leukemia. Pharmacotherapy 45(1):4\u201311","journal-title":"Pharmacotherapy"},{"key":"4059_CR193","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1423214","volume":"15","author":"C Lin","year":"2024","unstructured":"Lin C, Ma R, Zeng X, Zhang B, Cao T, Jiao S et al (2024) Integration of genomics, clinical characteristics and baseline biological profiles to predict the risk of liver injury induced by high-dose methotrexate. Front Pharmacol 15:1423214","journal-title":"Front Pharmacol"},{"key":"4059_CR194","doi-asserted-by":"publisher","first-page":"e82681","DOI":"10.1371\/journal.pone.0082681","volume":"9","author":"Y Liu","year":"2014","unstructured":"Liu Y, Yin Y, Sheng Q, Lu X, Wang F, Lin Z et al (2014) Association of ABCC2\u2009\u2013\u200924C\u2009>\u2009T polymorphism with high-dose methotrexate plasma concentrations and toxicities in childhood acute lymphoblastic leukemia. PLoS ONE 9:e82681. https:\/\/doi.org\/10.1371\/journal.pone.0082681","journal-title":"PLoS ONE"},{"issue":"10","key":"4059_CR195","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.3390\/medicina57101050","volume":"57","author":"J Gr\u017eelj","year":"2021","unstructured":"Gr\u017eelj J, Marovt M, Marko PB, Mlinari\u010d-Ra\u0161\u010dan I, Gmeiner T, \u0160mid A (2021) Polymorphism in gene for ABCC2 transporter predicts methotrexate drug survival in patients with psoriasis. Medicina 57(10):1050","journal-title":"Medicina"},{"issue":"6","key":"4059_CR196","doi-asserted-by":"publisher","first-page":"9388","DOI":"10.18632\/oncotarget.11543","volume":"8","author":"M Hegyi","year":"2016","unstructured":"Hegyi M, Arany A, Semsei AF, Csordas K, Eipel O, Gezsi A et al (2016) Pharmacogenetic analysis of high-dose methotrexate treatment in children with osteosarcoma. Oncotarget 8(6):9388","journal-title":"Oncotarget"},{"issue":"01","key":"4059_CR197","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1097\/BS9.0000000000000142","volume":"5","author":"Q Hao","year":"2023","unstructured":"Hao Q, Song Y, Fang Q, Lin Y, Chen L, Wang X et al (2023) Effects of genetic polymorphisms on methotrexate levels and toxicity in Chinese patients with acute lymphoblastic leukemia. Blood Sci 5(01):32\u201338","journal-title":"Blood Sci"},{"issue":"2","key":"4059_CR198","doi-asserted-by":"publisher","first-page":"169","DOI":"10.3109\/08880018.2013.870625","volume":"31","author":"MJ Sharifi","year":"2014","unstructured":"Sharifi MJ, Bahoush G, Zaker F, Ansari S, Rafsanjani KA, Sharafi H (2014) Association of-24CT, 1249GA, and 3972CT ABCC2 gene polymorphisms with methotrexate serum levels and toxic side effects in children with acute lymphoblastic leukemia. Pediatr Hematol Oncol 31(2):169\u2013177","journal-title":"Pediatr Hematol Oncol"},{"issue":"5","key":"4059_CR199","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1038\/tpj.2016.36","volume":"17","author":"B Jenko","year":"2017","unstructured":"Jenko B, Lusa L, Tomsic M, Praprotnik S, Dolzan V (2017) Clinical-pharmacogenetic predictive models for MTX discontinuation due to adverse events in rheumatoid arthritis. Pharmacogenomics J 17(5):412\u2013418","journal-title":"Pharmacogenomics J"},{"issue":"1","key":"4059_CR200","doi-asserted-by":"publisher","DOI":"10.1186\/s12969-021-00539-9","volume":"19","author":"N Kyvsgaard","year":"2021","unstructured":"Kyvsgaard N, Mikkelsen TS, Als TD, Christensen AE, Corydon TJ, Herlin T (2021) Single nucleotide polymorphisms associated with methotrexate-induced nausea in juvenile idiopathic arthritis. Pediatr Rheumatol Online J 19(1):51","journal-title":"Pediatr Rheumatol Online J"},{"key":"4059_CR201","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.clpt.2006.08.012","volume":"80","author":"T Rau","year":"2006","unstructured":"Rau T, Erney B, G\u00f6res R, Eschenhagen T, Beck J, Langer T (2006) High-dose methotrexate in pediatric acute lymphoblastic leukemia: impact of ABCC2 polymorphisms on plasma concentrations. Clin Pharmacol Ther 80:468\u2013476","journal-title":"Clin Pharmacol Ther"},{"key":"4059_CR202","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1097\/FPC.0b013e32835c3b24","volume":"23","author":"E Lopez-Lopez","year":"2013","unstructured":"Lopez-Lopez E, Ballesteros J, Pi\u00f1an MA, de Toledo JS, de Andoin NG, Garcia-Miguel P et al (2013) Polymorphisms in the methotrexate transport pathway: a new tool for MTX plasma level prediction in pediatric acute lymphoblastic leukemia. Pharm Genomics 23:53\u201361","journal-title":"Pharm Genomics"},{"key":"4059_CR203","first-page":"248","volume":"15","author":"MAH Den Hoed","year":"2015","unstructured":"Den Hoed MAH, Lopez-Lopez E, Te Winkel ML, Tissing W, de Rooij JDE, Gutierrez-Camino A et al (2015) Genetic and metabolic determinants of methotrexate-induced mucositis in pediatric acute lymphoblastic leukemia. Pharm J 15:248\u2013254","journal-title":"Pharm J"},{"issue":"9","key":"4059_CR204","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11092567","volume":"11","author":"C Membrive-Jim\u00e9nez","year":"2023","unstructured":"Membrive-Jim\u00e9nez C, Vieira-Maroun S, M\u00e1rquez-Pete N, Cura Y, P\u00e9rez-Ram\u00edrez C, Trcedor-S\u00e1nchez J, Jim\u00e9nez-Morales A, Ram\u00edrez-Tortosa M (2023) ABCC1, ABCG2 and FOXP3: Predictive Biomarkers of Toxicity from Methotrexate Treatment in Patients Diagnosed with Moderate-to-Severe Psoriasis. Biomedicines 11(9):2567","journal-title":"Biomedicines"},{"issue":"5","key":"4059_CR205","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24054431","volume":"24","author":"E da Silva Menezes","year":"2023","unstructured":"da Silva Menezes E, de Moraes FCA, de Nazar\u00e9 Cohen-Paes A, Wanderley AV, Pereira EEB, Pastana LF, Modesto AAC, de Assump\u00e7\u00e3o PP, Burbano RMR, Dos Santos SEB, Dos Santos NPC, Fernandes MR (2023) Influence of Genetic Variations in miRNA and Genes Encoding Proteins in the miRNA Synthesis Complex on Toxicity of the Treatment of Pediatric B-Cell ALL in the Brazilian Amazon. Int J Mol Sci 24(5):4431","journal-title":"Int J Mol Sci"},{"issue":"3","key":"4059_CR206","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0173472","volume":"12","author":"Y Li","year":"2017","unstructured":"Li Y, Liu S, Wang H, Mai H, Yuan X, Li C, Chen X, Wen F (2017) Methylation level of CpG islands in GGH gene promoter in pediatric acute leukemia. PLoS One 12(3):e0173472","journal-title":"PLoS One"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-026-04059-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-026-04059-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-026-04059-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T08:06:08Z","timestamp":1781078768000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-026-04059-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,9]]},"references-count":206,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["4059"],"URL":"https:\/\/doi.org\/10.1007\/s00228-026-04059-x","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,9]]},"assertion":[{"value":"17 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"149"}}